These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18676755)

  • 21. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
    Etienne MC; Pivot X; Formento JL; Bensadoun RJ; Formento P; Dassonville O; Francoual M; Poissonnet G; Fontana X; Schneider M; Demard F; Milano G
    Br J Cancer; 1999 Apr; 79(11-12):1864-9. PubMed ID: 10206306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
    Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
    Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
    Petrowsky H; Sturm I; Graubitz O; Kooby DA; Staib-Sebler E; Gog C; Köhne CH; Hillebrand T; Daniel PT; Fong Y; Lorenz M
    Eur J Surg Oncol; 2001 Feb; 27(1):80-7. PubMed ID: 11237496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters.
    Tullo A; D'Erchia AM; Honda K; Mitry RR; Kelly MD; Habib NA; Saccone C; Sbisà E
    Clin Cancer Res; 1999 Nov; 5(11):3523-8. PubMed ID: 10589767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.
    Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2002 Nov; 8(11):3468-74. PubMed ID: 12429636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disseminated colorectal tumor cells in organs prone to metastasis detected by new double enriched nested-PCR in comparison with recognized assays.
    Kraus MC; Linnemann U; Berger MR
    Oncol Rep; 2011 May; 25(5):1421-9. PubMed ID: 21369707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
    Georgieva M; Krasteva M; Angelova E; Ralchev K; Dimitrov V; Bozhimirov S; Georgieva E; Berger MR
    Oncol Rep; 2008 Jul; 20(1):3-11. PubMed ID: 18575712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer.
    Jiang Y; Kimchi ET; Staveley-O'Carroll KF; Cheng H; Ajani JA
    Cancer; 2009 Aug; 115(16):3609-17. PubMed ID: 19526592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.
    Al-Mulla F; Going JJ; Sowden ET; Winter A; Pickford IR; Birnie GD
    J Pathol; 1998 Jun; 185(2):130-8. PubMed ID: 9713338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of K-ras, Smad4 and p53 gene alterations in colorectal metastases and their role in the metastatic process.
    Losi L; Luppi G; Benhattar J
    Oncol Rep; 2004 Dec; 12(6):1221-5. PubMed ID: 15547741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotyping of K-ras codons 12 and 13 mutations in colorectal cancer by capillary electrophoresis.
    Chen YL; Chang YS; Chang JG; Wu SM
    J Chromatogr A; 2009 Jun; 1216(26):5147-54. PubMed ID: 19450806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor.
    Deng Y; Kurland BF; Wang J; Bi J; Li W; Rao S; Lan P; Lin T; Lin E
    Am J Clin Oncol; 2009 Jun; 32(3):245-52. PubMed ID: 19451802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
    Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
    Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: prognostic implications.
    Schimanski CC; Linnemann U; Galle PR; Arbogast R; Berger MR
    Int J Oncol; 2003 Sep; 23(3):791-6. PubMed ID: 12888919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural history of colorectal nonpolypoid adenomas: a prospective colonoscopic study and relation with cell kinetics and K-ras mutations.
    Watari J; Saitoh Y; Obara T; Fujiya M; Maemoto A; Ayabe T; Ashida T; Yokota K; Orii Y; Kohgo Y
    Am J Gastroenterol; 2002 Aug; 97(8):2109-15. PubMed ID: 12190185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Results of hepatic arterial infusion chemotherapy with 5-FU and leucovorin for unresectable liver metastases from colorectal cancer].
    Yamashita K; Urakami A; Kubota H; Nagatsuka R; Murakami H; Kawabe Y; Higashida M; Hirabayashi Y; Mikami Y; Ikeda M; Fuchimoto M; Yamamura M; Oka Y; Okumura H; Iki K; Matsumoto H; Imai S; Hirai T; Tsunoda T
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):71-6. PubMed ID: 18195531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
    Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
    Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.